# Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

> **NCT02107235** · PHASE1 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Head and Neck Neoplasms
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** oral rigosertib
- **DRUG:** cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02107235
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-10
- **Final completion:** 2015-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107235, "Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02107235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*